We are live on ! Find out more
IHE icon

iShares US Pharmaceuticals ETF

112 hedge funds and large institutions have $118M invested in iShares US Pharmaceuticals ETF in 2022 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 27 increasing their positions, 31 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

114% more call options, than puts

Call options by funds: $441K | Put options by funds: $206K

2.25% less ownership

Funds ownership: 33.21% → 30.96% (-2.3%)

10% less funds holding

Funds holding: 124 → 112 (-12)

13% less repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 31

34% less capital inflows, than outflows

Capital inflows: $19.5M | Capital outflows: $29.4M

63% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 19

Holders
112
Holders Change
-12
Holders Change %
-9.68%
% of All Funds
1.92%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
27
Reduced
31
Closed
19
Calls
$441​K
Puts
$206​K
Net Calls
+$235​K
Net Calls Change
+$235​K

IHE Hedge Fund Activity: Q3 2022 in Review

112 of the 5,833 institutional investors tracked by Wall St. Rank reported a position in iShares US Pharmaceuticals ETF (IHE) for Q3 2022, worth a combined $118M — down 18% from $143M a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of IHE and 7 opened new positions — a net loss of 12 holders — while 31 trimmed existing stakes and 27 added.

The largest buyer was Susquehanna International Group, adding an estimated $4.15M. The largest seller was EWG Elevate, exiting entirely with an estimated $6.35M sold.

  • 112 institutional investors held iShares US Pharmaceuticals ETF (IHE) as of Q3 2022, down from 124 in Q2 2022.
  • Funds reported $118M of iShares US Pharmaceuticals ETF stock for Q3 2022, down 18% quarter-over-quarter.
  • 7 funds opened new iShares US Pharmaceuticals ETF positions in Q3 2022 and 19 closed out, a net change of -12 holders.
  • The largest iShares US Pharmaceuticals ETF buyer in Q3 2022 was Susquehanna International Group, an estimated $4.15M added.
  • The largest iShares US Pharmaceuticals ETF seller in Q3 2022 was EWG Elevate, an estimated $6.35M sold.

Based on aggregated 13F filings for Q3 2022.